GnRH Agonist for Dual Trigger in IVF and for Luteal Phase Support in FET
Gonadotrophin Releasing Hormone Agonist for Dual Trigger in in Vitro Fertilization and for Luteal Phase Support in Frozen-thawed Embryo Transfer
The University of Hong Kong
784 participants
Sep 1, 2019
INTERVENTIONAL
Conditions
Summary
The objectives of this study are to compare the efficacy of the dual trigger group vs the hCG trigger group on the live birth rate in women undergoing IVF and the efficacy of the agonist in LP group vs the placebo group on the live birth rate in women undergoing FET.
Eligibility
Inclusion Criteria5
- IVF
- \- Women aged \<43 years at the time of IVF treatment
- Women aged \<43 years at the time of IVF treatment
- Replacing early cleavage embryos or blastocysts after thawing
- FET in natural cycles
Exclusion Criteria9
- Preimplantation genetic diagnosis treatment
- Use of donor oocytes or donor embryos
- Hydrosalpinx shown on pelvic scanning and not surgically treated
- Women at risk of OHSS
- FET
- Frozen early cleavage embryos thawed and cultured to blastocysts prior to transfer as requested by the patient
- Preimplantation genetic diagnosis treatment
- Use of donor oocytes or donor embryos
- Hydrosalpinx shown on pelvic scanning and not surgically treated
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and decapeptyl 0.2mg will be injected subcutaneously.
On the day of FET, decapeptyl 0.1 mg will be injected subcutaneously.
When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and normal saline will be injected subcutaneously.
On the day of FET, normal saline will be injected subcutaneously.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04064840